Ziarco Pharma raises €27M two years after founding

11/11/2014 - 2 minutes

Ziarco Group Ltd, a British biopharmaceutical start-up focusing on inflammatory skin diseases, bags €27M for Series B financing round. This fast-growing 2 year old company already raised €21.4M in a Serie A lead by Pfizer and is now accelerating even more. 

This second fundraising will enable clinical Phase II Proof-of-Concept studies for ZPL-389, a histamine H4 receptor antagonist for atopic dermatitis and ZPL-521, a topical cPLA2 inhibitor for psoriasis. ZPL-389 demonstrated an excellent safety and pharmacokinetic profile, the potential for once-daily dosing at a low dose, and complete inhibition of a relevant blood biomarker to confirm H4 specific drug activity. ZPL-521 is a potential best-in-class topical cytosolic phospholipase A2 (cPLA2) inhibitor. Its unique profile includes high potency, slow offset, and rapid systemic clearance. ZPL-521 demonstrated in a Phase I single ascending dose study via the inhaled route in healthy volunteers that it is safe and well-tolerated up to high doses.

Psoriasis and atopic dermatitis are chronic and relapsing inflammatory diseases of the skin associated with various immunologic abnormalities. The first one has a worldwide distribution and atopic dermatisis is affecting up to 15% of children in some areas.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

Support Us

Become a Member